| 1-Year Price Change | 57.3%Outperforming |
|---|---|
| Market Cap | ₹889.23 CrSmall Cap |
| P/E Ratio | 38.16Industry: 38.25 |
| Promoter Holding | 57.81%Stable |
| Metric | Q2-27 | Q1-27 | Q2-26 |
|---|---|---|---|
| Revenue from Operations | 217 | 174 | 169 |
| Other Income | 1.9 | 1.2 | 1.9 |
| Total Income | 219 | 176 | 171 |
| Profit Before Tax | 10.8 | 7.5 | 4.2 |
| Net Profit | 8.1 | 5.9 | 4.2 |
| Operating Margin | 4.9% | 4.3% | 2.5% |
| Net Profit QoQ | +37.3% | ||
| Net Profit YoY | +92.9% | ||
| Adj. Profit QoQ | +41.3% | ||
| Adj. Profit YoY | +287.0% | ||
Key highlights
- Net profit reached ₹8.1 crore in Q2 FY27, marking a 92.9% increase compared to the same quarter last year
- Revenue from operations grew 28.4% YoY to ₹217 crore, up from ₹169 crore in Q2 FY26
- Operating margins expanded to 4.9% from 2.5% in the previous year's corresponding quarter
- Company successfully migrated from the BSE SME platform to the Main Board of both BSE and NSE on October 27, 2026
- Board approved a significant fund-raising proposal of up to ₹1,500 crore through various securities including FCCBs
- The company discontinued manufacturing at its Palghar unit to rationalize costs and minimize losses
Operational Restructuring and Margin Expansion
Sudarshan Pharma Industries reported a notable expansion in its operating margin, which reached 4.9% in Q2 FY27 compared to 2.5% in the year-ago period. A key driver for this efficiency gain was the management's decision to discontinue manufacturing operations at the Palghar unit during the quarter. This closure is intended to rationalize fixed and operating costs while enabling the company to focus on more sustainable and profitable operations.
The company also benefited from a litigation win in a Dubai court against Regans International DMCC, receiving ₹7.48 crore of a total ₹9.18 crore award as of September 30, 2026.
Strategic Divestments and Global Expansion
- Incorporated Sudarshan Industries Inc. as a wholly-owned subsidiary in the USA on June 5, 2026
- Completed the sale of 51% stake in Ishwari Healthcare Private Limited on September 28, 2026, for ₹1.40 crore
- Allotted 48.11 lakh equity shares on August 19, 2026, following the conversion of Foreign Currency Convertible Bonds
- Received board consent to raise up to ₹1,500 crore to fuel future growth and working capital requirements
- Consolidated total assets grew to ₹761.95 crore as of September 30, 2026, up from ₹641.74 crore in March 2026
Corporate Milestones and Market Transition
The quarter marked a significant corporate milestone as Sudarshan Pharma completed its migration from the SME Platform to the Main Board of the National Stock Exchange and BSE Limited. This transition, effective from late October 2026, is expected to enhance liquidity and institutional participation. On the financial front, the company maintained a debt-to-equity ratio of 2.03.
Interest coverage improved to 2.06 during the quarter, reflecting better earnings capacity relative to finance costs. The company is currently tracking toward its previously stated goal of achieving a minimum export turnover of ₹100 crore for the full fiscal year 2026-27.
| Date | Announcement | Amount |
|---|---|---|
| 12 Aug 2026 | Q1 FY27 consolidated revenue from operationsSource: fyers.in | ₹174.42 Cr |
| 30 Apr 2026 | Q4 FY26 consolidated revenue from operationsSource: arthneeti.com | ₹220.90 Cr |
| 28 Jan 2026 | Q3 FY26 consolidated revenue from operationsSource: fyers.in | ₹168.00 Cr |
| 18 Oct 2025 | Q2 FY26 consolidated revenue from operationsSource: fyers.in | ₹169.10 Cr |
| 14 Aug 2025 | Q1 FY26 consolidated revenue from operationsSource: BSE filing | ₹145.26 Cr |
| 24 Apr 2025 | Q4 FY25 consolidated revenue from operationsSource: fyers.in | ₹162.48 Cr |
What to watch next
- Completion of 9.50% equity stake acquisition in US-based MedTherapy Biotechnology Inc by March 31, 2027
- Utilization and deployment of funds from the newly approved ₹1,500 crore fund-raising plan
- Progress toward the ₹100 crore export turnover target for FY 2026-27
| Share price | ₹36.95 |
|---|---|
| Market capitalisation | ₹889.23 Cr |
| Revenue (annual) | ₹703.06 Cr |
| Net profit (annual) | ₹23.30 Cr |
| Revenue (latest quarter) | ₹174.42 Cr-21.05% vs previous quarter |
| Net profit (latest quarter) | ₹5.36 Cr-49.99% vs previous quarter |
| P/E (TTM) | 38.16×Sector 34.09× |
| Promoter holding | 57.81%-1.12% QoQ |
| FII holding | 21.94%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Sudarshan Pharma Industries Ltd announcing Unaudited Standalone and Consolidated Financial Results for Q2 FY27. Market figures from a third-party data provider.
